BRIEF-Delmar Pharmaceuticals HGRAC approves application to initiate phase 2 of VAL-083
July 24, 2017 at 08:55 AM EDT
* Delmar Pharmaceuticals receives approval from China's Human Genetic Resources Administration to initiate phase 2 clinical trial in newly diagnosed GBM
